PRISM Pharma Co., Ltd.
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
5
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Trial to Evaluate Topical C-82 in a Psoriasis Plaque Test
- Conditions
- Psoriasis
- Interventions
- Drug: C-82 Topical Gel, 1%Drug: C-82 Topical Gel, PlaceboDrug: Daivonex creamDrug: Diprosis gel
- First Posted Date
- 2015-05-01
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT02432027
Trial of Topical C-82 in Systemic Sclerosis - A Phase I/II Biomarker and Safety Trial
- Conditions
- Systemic Scleroderma
- Interventions
- Drug: C-82 Topical Gel, PlaceboDrug: C-82 Topical Gel, 1%
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 17
- Registration Number
- NCT02349009
Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma
- Conditions
- Pancreatic AdenocarcinomaMetastatic Pancreatic CancerAdvanced Pancreatic Cancer
- Interventions
- First Posted Date
- 2013-01-09
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT01764477
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Myeloid Malignancies
- First Posted Date
- 2012-05-25
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 49
- Registration Number
- NCT01606579
- Locations
- 🇺🇸
Emory University / Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸University of Massachusetts Medical Center, Worcester, Massachusetts, United States
🇺🇸New Mexico Cancer Care Alliance, Albuquerque, New Mexico, United States
Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2011-02-24
- Last Posted Date
- 2017-08-17
- Lead Sponsor
- Prism Pharma Co., Ltd.
- Target Recruit Count
- 23
- Registration Number
- NCT01302405
- Locations
- 🇺🇸
Mayo Clinic, Scottsdale, Arizona, United States
🇺🇸University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Mayo Clinic, Department of Oncology, Rochester, Minnesota, United States